Last reviewed · How we verify
Stimus (NNG-DEPO)
Stimus (NNG-DEPO) is a Central nervous system stimulant Biologic drug developed by Nanogen Pharmaceutical Biotechnology Joint Stock Company. It is currently in Phase 3 development for Attention deficit hyperactivity disorder (ADHD), Narcolepsy.
Stimus (NNG-DEPO) is a stimulant medication that works by increasing the levels of certain neurotransmitters in the brain.
Stimus (NNG-DEPO) is a stimulant medication that works by increasing the levels of certain neurotransmitters in the brain. Used for Attention deficit hyperactivity disorder (ADHD), Narcolepsy.
At a glance
| Generic name | Stimus (NNG-DEPO) |
|---|---|
| Sponsor | Nanogen Pharmaceutical Biotechnology Joint Stock Company |
| Drug class | Central nervous system stimulant |
| Modality | Biologic |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Stimus (NNG-DEPO) is a central nervous system stimulant that increases the levels of dopamine and norepinephrine in the brain, which can help improve focus, attention, and impulse control. It is used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy.
Approved indications
- Attention deficit hyperactivity disorder (ADHD)
- Narcolepsy
Common side effects
- Insomnia
- Headache
- Anxiety
- Nervousness
- Dizziness
Key clinical trials
- Pharmacokinetic/Pharmacodynamic Parameters of NNG-DEPO (Stimus) With Aranesp® (Amgen) in Treatment of Anemia in CKD Patients on Dialysis (PHASE1)
- A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Stimus (NNG-DEPO) CI brief — competitive landscape report
- Stimus (NNG-DEPO) updates RSS · CI watch RSS
- Nanogen Pharmaceutical Biotechnology Joint Stock Company portfolio CI
Frequently asked questions about Stimus (NNG-DEPO)
What is Stimus (NNG-DEPO)?
How does Stimus (NNG-DEPO) work?
What is Stimus (NNG-DEPO) used for?
Who makes Stimus (NNG-DEPO)?
What drug class is Stimus (NNG-DEPO) in?
What development phase is Stimus (NNG-DEPO) in?
What are the side effects of Stimus (NNG-DEPO)?
Related
- Drug class: All Central nervous system stimulant drugs
- Manufacturer: Nanogen Pharmaceutical Biotechnology Joint Stock Company — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Attention deficit hyperactivity disorder (ADHD)
- Indication: Drugs for Narcolepsy
- Compare: Stimus (NNG-DEPO) vs similar drugs
- Pricing: Stimus (NNG-DEPO) cost, discount & access